Author

V. Bergo

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cell Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:mouse· 2 Assay:bulk RNA-seq· 1 Research Focus:cell-cell communication· 1 Research Focus:host-pathogen & immune response· 1

Frequent Co-Authors

E. Trompouki· 2 shared A. Boumpas· 1 shared A. Emelyanov· 1 shared A. Hatzioannou· 1 shared A. J. Fornace· 1 shared A. Pierantoni· 1 shared A. S. Papaioannou· 1 shared A. Tasis· 1 shared

Activity by Year

2023-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCell Biology

E. Trompouki

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

p16High immune cell - controlled disease tolerance as a broad defense and healthspan extending strategy

F. Triana-Martinez, A. Pierantoni, D. Graca, V. Bergo, A. Emelyanov, B. Grigorash, S. Tsuji, S. Nakano, L. Grosse, V. Brglez, P. Marty, J. Dellamonica, A. J. Fornace, E. Trompouki, H. Eiji, , D. V. Bulavin

This study identifies p16High immune cells as critical for disease tolerance, showing they enhance survival in various conditions and extend healthspan by maintaining low adenosine levels.

bioRxiv · Jul 15, 2024Cell Biology

PD-L1 blockade immunotherapy rewires cancer emergency myelopoiesis

A. Boumpas, A. S. Papaioannou, P. Bousounis, M. Grigoriou, V. Bergo, I. Papafragkos, A. Tasis, M. Iskas, L. Boon, M. Makridakis, A. Vlahou, E. Gavriilaki, A. Hatzioannou, I. Mitroulis, E. Trompouki, P. Verginis

This study shows PD-L1 blockade in tumor-bearing mice targets bone marrow HSPCs, reprograms their transcriptome toward inflammation, and reduces myeloid-derived suppressor cells.

bioRxiv · Dec 20, 2023 · PreprintImmunology